{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:53:53Z","timestamp":1790502833576,"version":"4.1.0"},"reference-count":287,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303238"],"award-info":[{"award-number":["82303238"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402108"],"award-info":[{"award-number":["82402108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502196"],"award-info":[{"award-number":["82502196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2026NSFSC1765"],"award-info":[{"award-number":["2026NSFSC1765"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["22ZDYF1357"],"award-info":[{"award-number":["22ZDYF1357"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["2024NSFSC1761"],"award-info":[{"award-number":["2024NSFSC1761"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031514","name":"Health Commission of Chengdu Municipality","doi-asserted-by":"publisher","award":["2024014"],"award-info":[{"award-number":["2024014"]}],"id":[{"id":"10.13039\/100031514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031514","name":"Health Commission of Chengdu Municipality","doi-asserted-by":"publisher","award":["2024063"],"award-info":[{"award-number":["2024063"]}],"id":[{"id":"10.13039\/100031514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019014","name":"Chengdu Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["2024-YF05\\u201302098-SN"],"award-info":[{"award-number":["2024-YF05\\u201302098-SN"]}],"id":[{"id":"10.13039\/501100019014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019014","name":"Chengdu Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["2024-YF05\\u201301028-SN"],"award-info":[{"award-number":["2024-YF05\\u201301028-SN"]}],"id":[{"id":"10.13039\/501100019014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025 M771475"],"award-info":[{"award-number":["2025 M771475"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025 M772671"],"award-info":[{"award-number":["2025 M772671"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104079","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:54:19Z","timestamp":1779231259000},"page":"104079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["B cells in systemic lupus erythematosus: from pathogenic mechanisms to targeted therapies"],"prefix":"10.1016","volume":"25","author":[{"given":"Xu","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqiang","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangbin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0005","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","article-title":"Updated assessment of the prevalence, spectrum and case definition of autoimmune disease","volume":"11","author":"Hayter","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102531","article-title":"Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014","volume":"19","author":"Scherlinger","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104079_bb0015","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1016\/S0140-6736(16)30266-5","article-title":"Systemic lupus erythematosus","volume":"387","author":"Barnett","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2022-223035","article-title":"Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study","volume":"82","author":"Tian","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0025","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","article-title":"Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis","volume":"42","author":"Fatoye","year":"2022","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0030","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T Cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104079_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"issue":"10188","key":"10.1016\/j.autrev.2026.104079_bb0045","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","article-title":"Novel paradigms in systemic lupus erythematosus","volume":"393","author":"D\u00f6rner","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update \u03bfn the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10188","key":"10.1016\/j.autrev.2026.104079_bb0060","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104079_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/BOR.0000000000000865","article-title":"B cells in systemic lupus erythematosus","volume":"34","author":"Szelinski","year":"2022","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0075","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Review: abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s43556-024-00217-8","article-title":"Systemic lupus erythematosus: pathogenesis and targeted therapy","volume":"5","author":"Su","year":"2024","journal-title":"Mol Biomed"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.rdc.2021.04.006","article-title":"B cells in systemic lupus erythematosus","volume":"47","author":"Canny","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0961203316643172","article-title":"B-cell subsets, signaling and their roles in secretion of autoantibodies","volume":"25","author":"Iwata","year":"2016","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"806","key":"10.1016\/j.autrev.2026.104079_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abn5410","article-title":"TRIM55 promotes noncanonical NF-\u03baB signaling and B cell-mediated immune responses by coordinating p100 ubiquitination and processing","volume":"16","author":"Lin","year":"2023","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/08916934.2019.1700232","article-title":"The pathological role of B cells in systemic lupus erythematosus: from basic research to clinical","volume":"53","author":"Feng","year":"2019","journal-title":"Autoimmunity"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0110","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-065X.1999.tb01310.x","article-title":"The central and multiple roles of B cells in lupus pathogenesis","volume":"169","author":"Chan","year":"2006","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0120","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1172\/JCI113979","article-title":"Induction of excessive B cell proliferation and differentiation by an in vitro stimulus in culture in human systemic lupus erythematosus","volume":"83","author":"Suzuki","year":"1989","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0130","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nri.2017.19","article-title":"Mechanisms of central tolerance for B cells","volume":"17","author":"Nemazee","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000527213","article-title":"Aberrant B-cell activation in systemic lupus erythematosus","volume":"8","author":"Kang","year":"2022","journal-title":"Kidney Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0145","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1084\/jem.20062567","article-title":"BAFF and MyD88 signals promote a lupuslike disease independent of T cells","volume":"204","author":"Groom","year":"2007","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0150","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/1074-7613(95)90179-5","article-title":"Anatomy of autoantibody production: dominant localization of antibody-producing cells to T cell zones in fas-deficient mice","volume":"3","author":"Jacobson","year":"1995","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"5589","key":"10.1016\/j.autrev.2026.104079_bb0160","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1126\/science.1073924","article-title":"Evolution of autoantibody responses via somatic hypermutation outside of germinal centers","volume":"297","author":"William","year":"2002","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0165","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2249.1992.tb03042.x","article-title":"Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression","volume":"88","author":"Kitani","year":"1992","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0175","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":"Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0180","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1084\/jem.20170580","article-title":"B cell\u2013derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0185","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","article-title":"Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification","volume":"75","author":"Munroe","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0190","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.rdc.2007.02.005","article-title":"Neonatal lupus syndromes","volume":"33","author":"Izmirly","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"issue":"16","key":"10.1016\/j.autrev.2026.104079_bb0195","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0625.2010.01064.x","article-title":"Deposition of chromatin-IgG complexes in skin of nephritic MRL-lpr\/lpr mice is associated with increased local matrix metalloprotease activities","volume":"19","author":"Hedberg","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2026.104079_bb0205","doi-asserted-by":"crossref","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","article-title":"Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target","volume":"132","author":"Lou","year":"2022","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0210","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.4049\/jimmunol.168.6.3072","article-title":"\u0391-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies","volume":"168","author":"Deocharan","year":"2002","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.1995.341","article-title":"Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice","volume":"48","author":"Ehrenstein","year":"1995","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0220","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.4049\/jimmunol.181.10.7367","article-title":"Sunlight triggers cutaneous lupus through a CSF-1-dependent mechanism in MRL-Fas lpr mice","volume":"181","author":"Menke","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jaut.2016.08.005","article-title":"Current trends in autoimmunity and the nervous system","volume":"75","author":"Selmi","year":"2016","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0230","article-title":"Age-associated B Cells (ABCs) in the prognosis, diagnosis and therapy of systemic lupus erythematosus (SLE)","volume":"31","author":"Garyfallos","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"23","key":"10.1016\/j.autrev.2026.104079_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314688","article-title":"Different types of chronic inflammation engender distinctive Immunosenescent profiles in affected patients","volume":"23","author":"Moysidou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0240","article-title":"Investigating the role of T-bet+ B Cells (ABCs\/DN) in the immunopathogenesis of systemic lupus erythematosus","volume":"34","author":"Garyfallos","year":"2023","journal-title":"Mediterr J Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0245","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.3390\/cimb45080421","article-title":"Increase in double negative B lymphocytes in patients with systemic lupus erythematosus in remission and their correlation with early differentiated T lymphocyte subpopulations","volume":"45","author":"Moysidou","year":"2023","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0250","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217341","article-title":"Functions of double-negative B cells in autoimmune diseases, infections, and cancers","volume":"15","author":"Chung","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2026.104079_bb0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","article-title":"IgD\u2212CD27\u2212 double negative (DN) B cells: origins and functions in health and disease","volume":"255","author":"Beckers","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1016\/j.autrev.2026.104079_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/254245","article-title":"The expansion of CD25highIL-10highFoxP3highB regulatory cells is in association with SLE disease activity","volume":"2015","author":"Vadasz","year":"2015","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0265","article-title":"T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus","volume":"9","author":"Rieux-Laucat","year":"2014","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0270","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1191\/0961203303lu338oa","article-title":"Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells","volume":"12","author":"Kashipaz","year":"2003","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaut.2004.10.001","article-title":"IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus","volume":"23","author":"D\u00edaz-Alderete","year":"2004","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-35209-1","article-title":"Single-cell sequencing shows cellular heterogeneity of cutaneous lesions in lupus erythematosus","volume":"13","author":"Zheng","year":"2022","journal-title":"Nat Commun"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2026.104079_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00351161","article-title":"Clinical relevance of autoantibodies in systemic rheumatic diseases","volume":"23","author":"Fritzler","year":"1996","journal-title":"Mol Biol Rep"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0290","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.23712","article-title":"Antinuclear antibody\u2013negative systemic lupus erythematosus in an international inception cohort","volume":"71","author":"Choi","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4049\/jimmunol.160.1.51","article-title":"A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr\/lpr mice","volume":"160","author":"Chan","year":"1998","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0300","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.immuni.2010.11.025","article-title":"Dendritic cells in lupus are not required for activation of T and B Cells but promote their expansion, resulting in tissue damage","volume":"33","author":"Teichmann","year":"2010","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0305","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.20110200","article-title":"WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity","volume":"208","author":"Becker-Herman","year":"2011","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0310","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.1500792","article-title":"B cell\u2013specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus","volume":"195","author":"Giles","year":"2015","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0315","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104079_bb0320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coi.2015.01.018","article-title":"B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production","volume":"33","author":"Jackson","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0325","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri.2017.24","article-title":"Altered B cell signalling in autoimmunity","volume":"17","author":"Rawlings","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0330","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.4049\/jimmunol.174.4.1775","article-title":"B cell selection and susceptibility to autoimmunity","volume":"174","author":"Grimaldi","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.021908.132541","article-title":"B cell signaling and fate decision","volume":"28","author":"Kurosaki","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0340","doi-asserted-by":"crossref","DOI":"10.1186\/ar1155","article-title":"Flow cytometric assessment of the signaling status of human B lymphocytes from normal and autoimmune individuals","volume":"6","author":"Grammer","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0345","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1172\/JCI119073","article-title":"B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events","volume":"98","author":"Liossis","year":"1996","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0350","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1084\/jem.20051503","article-title":"Selective dysregulation of the Fc\u03b3IIB receptor on memory B cells in SLE","volume":"203","author":"Mackay","year":"2006","journal-title":"J Exp Med"},{"issue":"246","key":"10.1016\/j.autrev.2026.104079_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009131","article-title":"Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0360","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0365","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cr.2010.177","article-title":"Non-canonical NF-\u03baB signaling pathway","volume":"21","author":"Sun","year":"2010","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0370","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0375","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.it.2013.01.004","article-title":"Regulation of nuclear factor-\u03baB in autoimmunity","volume":"34","author":"Sun","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2010\/207578","article-title":"Association ofTNFAIP3Polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population","volume":"2010","author":"Kawasaki","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0385","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.molimm.2013.07.006","article-title":"Genetic interaction between genes involved in NF-\u03baB signaling pathway in systemic lupus erythematosus","volume":"56","author":"Cen","year":"2013","journal-title":"Mol Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0390","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ng.202","article-title":"Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus","volume":"40","author":"Musone","year":"2008","journal-title":"Nat Genet"},{"issue":"24","key":"10.1016\/j.autrev.2026.104079_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415998","article-title":"Unraveling the link between interferon-\u03b1 and systemic lupus erythematosus: from the molecular mechanisms to target therapies","volume":"23","author":"Infante","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104079_bb0400","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaut.2018.11.004","article-title":"NF-kB signaling in myeloid cells mediates the pathogenesis of immune-mediated nephritis","volume":"98","author":"Chalmers","year":"2019","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0405","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03173.x","article-title":"Toll-like receptors \u2013 sentries in the B-cell response","volume":"128","author":"Bekeredjian-Ding","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104079_bb0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/381418","article-title":"Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear Cells from patients with systemic lupus erythematosus","volume":"2014","author":"Klonowska-Szymczyk","year":"2014","journal-title":"Mediat Inflamm"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0415","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1002\/art.22197","article-title":"Expansion of toll-like receptor 9\u2013expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process","volume":"54","author":"Papadimitraki","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0420","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.immuni.2012.11.017","article-title":"Signals via the adaptor MyD88 in B Cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus","volume":"38","author":"Teichmann","year":"2013","journal-title":"Immunity"},{"issue":"44","key":"10.1016\/j.autrev.2026.104079_bb0425","doi-asserted-by":"crossref","first-page":"15989","DOI":"10.1073\/pnas.0508327102","article-title":"Negative regulation of toll-like-receptor signaling by IRF-4","volume":"102","author":"Negishi","year":"2005","journal-title":"Proc Natl Acad Sci"},{"issue":"43","key":"10.1016\/j.autrev.2026.104079_bb0430","doi-asserted-by":"crossref","first-page":"15416","DOI":"10.1073\/pnas.0406933101","article-title":"Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in toll-like receptor signaling","volume":"101","author":"Honda","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0435","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni1118","article-title":"Interferon-\u03b1 induction through toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6","volume":"5","author":"Kawai","year":"2004","journal-title":"Nat Immunol"},{"issue":"7030","key":"10.1016\/j.autrev.2026.104079_bb0440","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature03308","article-title":"Integral role of IRF-5 in the gene induction programme activated by toll-like receptors","volume":"434","author":"Takaoka","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0445","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1681\/ASN.2010121260","article-title":"IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production","volume":"22","author":"Lech","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0450","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ni968","article-title":"SIGIRR, a negative regulator of toll-like receptor\u2013interleukin 1 receptor signaling","volume":"4","author":"Wald","year":"2003","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0455","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1084\/jem.20072646","article-title":"Tir8\/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens","volume":"205","author":"Lech","year":"2008","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0460","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/path.2678","article-title":"Lack of SIGIRR\/TIR8 aggravates hydrocarbon oil-induced lupus nephritis","volume":"220","author":"Lech","year":"2010","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0465","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000182","article-title":"Roles of the NF- B pathway in lymphocyte development and function","volume":"2","author":"Gerondakis","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0470","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1600-065X.2011.01059.x","article-title":"Non-canonical NF-\u03baB signaling activation and regulation: principles and perspectives","volume":"244","author":"Razani","year":"2011","journal-title":"Immunol Rev"},{"issue":"18","key":"10.1016\/j.autrev.2026.104079_bb0475","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1101\/gad.1228704","article-title":"Signaling to NF-\u03baB","volume":"18","author":"Hayden","year":"2004","journal-title":"Genes Dev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0480","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/cr.2011.13","article-title":"NF-\u03baB in immunobiology","volume":"21","author":"Hayden","year":"2011","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0485","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4049\/jimmunol.1401514","article-title":"Conditional deletion of NF-\u03baB\u2013inducing kinase (NIK) in adult mice disrupts mature B cell survival and activation","volume":"195","author":"Brightbill","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00509","article-title":"Non-canonical NF-\u03baB signaling initiated by BAFF influences B cell biology at multiple junctures","volume":"4","author":"Gardam","year":"2014","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0495","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cytogfr.2010.06.002","article-title":"NF-\u03baB inducing kinase: a key regulator in the immune system and in cancer","volume":"21","author":"Thu","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0500","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0846-4","article-title":"Fn14-fc suppresses germinal center formation and pathogenic B cells in a lupus mouse model via inhibition of the TWEAK\/Fn14 pathway","volume":"14","author":"Min","year":"2016","journal-title":"J Transl Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0505","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/ni.2423","article-title":"The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-\u03baB signaling","volume":"13","author":"Jin","year":"2012","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.716469","article-title":"NF-\u03baB: at the borders of autoimmunity and inflammation","volume":"12","author":"Barnabei","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0515","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/j.celrep.2014.11.024","article-title":"A pathway switch directs BAFF signaling to distinct NF\u03baB transcription factors in maturing and proliferating B cells","volume":"9","author":"Almaden","year":"2014","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0520","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2249.2009.04007.x","article-title":"BAFF: a local and systemic target in autoimmune diseases","volume":"158","author":"Moisini","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0525","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in autoimmunity","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0530","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clim.2008.12.009","article-title":"B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus","volume":"131","author":"Parameswaran","year":"2009","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105627","article-title":"Type 1 interferons: a target for immune-mediated inflammatory diseases (IMIDs)","volume":"91","author":"Mathian","year":"2024","journal-title":"Joint Bone Spine"},{"issue":"642","key":"10.1016\/j.autrev.2026.104079_bb0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn2263","article-title":"Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation","volume":"14","author":"Billi","year":"2022","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0545","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1093\/rheumatology\/keaa167","article-title":"Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers","volume":"59","author":"Chasset","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001032","article-title":"Burden of Systemic Lupus Erythematosus in clinical practice: baseline data from the SLE prospective observational cohort study (SPOCS) by interferon gene signature","volume":"10","author":"Arnaud","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101865","article-title":"New and future therapies: changes in the therapeutic armamentarium for SLE","volume":"37","author":"Askanase","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0560","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0565","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0570","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-\u03b1 pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0575","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti\u2013RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0580","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4049\/jimmunol.1302112","article-title":"Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus","volume":"192","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0585","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.4049\/jimmunol.181.9.5875","article-title":"Autoreactive B Cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-\u03b1","volume":"181","author":"Uccellini","year":"2008","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0590","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.4049\/jimmunol.174.7.4043","article-title":"Plasmacytoid dendritic Cells control TLR7 sensitivity of naive B Cells via type I IFN","volume":"174","author":"Bekeredjian-Ding","year":"2005","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0595","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/icb.2012.10","article-title":"Role of type I interferons in the activation of autoreactive B cells","volume":"90","author":"Kiefer","year":"2012","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0600","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1006\/bbrc.2001.5025","article-title":"Interferon-\u03b1 promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase","volume":"284","author":"Ruuth","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0605","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2010.02.012","article-title":"Type I interferon (IFN-\u03b1\/\u03b2) rescues B-lymphocytes from apoptosis via PI3K\u03b4\/Akt, rho-a, NF\u03baB and Bcl-2\/BclXL","volume":"263","author":"Badr","year":"2010","journal-title":"Cell Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0610","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2015.01.009","article-title":"Interferon-\u03b1 induces altered transitional B cell signaling and function in systemic lupus erythematosus","volume":"58","author":"Chang","year":"2015","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0615","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0620","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0625","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"R\u00f6nnblom","year":"1991","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0630","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0635","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0640","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0645","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0650","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","article-title":"Pragmatic approaches to therapy for systemic lupus erythematosus","volume":"10","author":"Xiong","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0655","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104079_bb0660","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb0665","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nrrheum.2010.68","article-title":"B cells as therapeutic targets in SLE","volume":"6","author":"Sanz","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"24","key":"10.1016\/j.autrev.2026.104079_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis\u2014role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0675","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cmi.2012.64","article-title":"B-cell-targeted therapies in systemic lupus erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0680","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"issue":"15","key":"10.1016\/j.autrev.2026.104079_bb0685","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","article-title":"Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc\u03b3RIIb with fc-engineered antibodies","volume":"45","author":"Chu","year":"2008","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0690","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4161\/mabs.28841","article-title":"Suppression of innate and adaptive B cell activation pathways by antibody coengagement of Fc\u03b3RIIb and CD19","volume":"6","author":"Szili","year":"2014","journal-title":"mAbs"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0695","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single Centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0700","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0705","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.4049\/jimmunol.1501376","article-title":"Autoreactive CD19+CD20\u2212 plasma cells contribute to disease severity of experimental autoimmune encephalomyelitis","volume":"196","author":"Chen","year":"2016","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0710","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: first approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0715","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma Cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J Immunol"},{"issue":"47","key":"10.1016\/j.autrev.2026.104079_bb0720","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0725","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s12016-007-8028-z","article-title":"Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?","volume":"34","author":"Galarza","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0730","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.079095","article-title":"Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response","volume":"67","author":"J\u00f3nsd\u00f3ttir","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0735","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0740","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0745","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0750","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-6143.2011.03833.x","article-title":"In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells","volume":"12","author":"Kamburova","year":"2012","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0755","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence","volume":"41","author":"Narv\u00e1ez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0760","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0765","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0770","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0775","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0780","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0785","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ib\u00e1\u00f1ez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0790","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study","volume":"21","author":"Fern\u00e1ndez-Nebro","year":"2012","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0795","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of Belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0800","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0805","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus \u2014 past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb0810","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of Ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0815","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0820","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0825","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.15232","article-title":"A tale of two antibodies: obinutuzumab versus rituximab","volume":"182","author":"Freeman","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2026.104079_bb0830","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2516150","article-title":"Efficacy and safety of obinutuzumab in active systemic lupus erythematosus","author":"Furie","year":"2026","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0835","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0840","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ckj\/sfw022","article-title":"Ofatumumab treatment in lupus nephritis patients","volume":"9","author":"Haarhaus","year":"2016","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0845","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/rheumatology\/keu475","article-title":"Ofatumumab: a novel treatment for severe systemic lupus erythematosus","volume":"54","author":"Thornton","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0850","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-018-0278-1","article-title":"Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C \u03b4","volume":"16","author":"Lei","year":"2018","journal-title":"Pediatr Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0855","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0961203320981137","article-title":"Ofatumumab use in juvenile systemic lupus erythematosus: a single centre experience","volume":"30","author":"Cinar","year":"2020","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0860","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-3083.2002.01063.x","article-title":"Expression and function of CD22, a B-cell restricted molecule*","volume":"55","author":"MoyrOn-QuirOz","year":"2002","journal-title":"Scand J Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb0865","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1073\/pnas.95.8.4504","article-title":"Immune regulation by the ST6Gal sialyltransferase","volume":"95","author":"Hennet","year":"1998","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0870","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/08830185.2012.709890","article-title":"CD22 and autoimmune disease","volume":"31","author":"D\u00f6rner","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0875","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0880","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.autrev.2015.07.013","article-title":"The mechanistic impact of CD22 engagement with epratuzumab on B cell function: implications for the treatment of systemic lupus erythematosus","volume":"14","author":"D\u00f6rner","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0885","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0890","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb0895","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/1744666X.2018.1450141","article-title":"Epratuzumab for the treatment of systemic lupus erythematosus","volume":"14","author":"Geh","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0900","first-page":"1500","article-title":"Anti-CD22 epratuzumab for systemic lupus erythematosus: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Li","year":"2019","journal-title":"Exp Ther Med"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0905","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/bmm-2021-0575","article-title":"Cd38 a biomarker and therapeutic target in non-hematopoietic tumors","volume":"16","author":"Barrientos-Robledo","year":"2022","journal-title":"Biomark Med"},{"key":"10.1016\/j.autrev.2026.104079_bb0910","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0915","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated CD38 expression on peripheral blood immune cell subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0920","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb0925","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with Daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb0930","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0935","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/jpet.119.256602","article-title":"A reduction in B, T, and natural killer cells expressing CD38 by TAK-079 inhibits the induction and progression of collagen-induced arthritis in cynomolgus monkeys","volume":"370","author":"Korver","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0940","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0945","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1073\/pnas.96.1.185","article-title":"A two-step, two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0950","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb0955","doi-asserted-by":"crossref","first-page":"097","DOI":"10.1385\/IR:24:2:097","article-title":"Signaling by CD40 and its mimics in B cell activation","volume":"24","author":"Bishop","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2026.104079_bb0960","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786144","article-title":"Anti-CD40 antibody fused to CD40 ligand is a superagonist platform for adjuvant intrinsic DC-targeting vaccines","volume":"12","author":"Ceglia","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb0965","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1177\/0961203320941931","article-title":"CD40 and CD72 expression and prognostic values among children with systemic lupus erythematosus: a case\u2013control study","volume":"29","author":"Asmiyou","year":"2020","journal-title":"Lupus"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb0970","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/art.42557","article-title":"Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial","volume":"75","author":"Jayne","year":"2023","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb0975","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005557","article-title":"Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study","volume":"11","author":"Shen","year":"2025","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb0980","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","article-title":"BAFF, APRIL and their receptors: structure, function and signaling","volume":"18","author":"Bossen","year":"2006","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2026.104079_bb0985","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb0990","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1893501","article-title":"BAFF receptor antibody for mantle cell lymphoma therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.autrev.2026.104079_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111827","article-title":"The role of BAFF and BAFF-R inhibitors in the treatment of immune thrombocytopenia; a focused review","volume":"131","author":"Nilforoushzadeh","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1000","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-immunol-030409-101216","article-title":"Early events in B cell activation","volume":"28","author":"Harwood","year":"2010","journal-title":"Annu Rev Immunol"},{"issue":"5537","key":"10.1016\/j.autrev.2026.104079_bb1005","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1126\/science.1061965","article-title":"BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF","volume":"293","author":"Thompson","year":"2001","journal-title":"Science"},{"issue":"45","key":"10.1016\/j.autrev.2026.104079_bb1010","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.1074\/jbc.M005224200","article-title":"Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS","volume":"275","author":"Wu","year":"2000","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.autrev.2026.104079_bb1015","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1073\/pnas.160213497","article-title":"B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1","volume":"97","author":"Shu","year":"2000","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1020","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-016-0015-4","article-title":"BAFF- and APRIL-targeted therapy in systemic autoimmune diseases","volume":"36","author":"Nakayamada","year":"2016","journal-title":"Inflamm Regener"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0165-2478(03)00050-6","article-title":"BAFF and the regulation of B cell survival","volume":"88","author":"Schneider","year":"2003","journal-title":"Immunol Lett"},{"issue":"6781","key":"10.1016\/j.autrev.2026.104079_bb1030","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb1040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb1045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"5425","key":"10.1016\/j.autrev.2026.104079_bb1050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1055","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1060","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for Baff develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4049\/jimmunol.175.1.319","article-title":"\u0394BAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models","volume":"175","author":"Gavin","year":"2005","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb1070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(02)00425-9","article-title":"BAFF\/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-\u03baB2","volume":"17","author":"Kayagaki","year":"2002","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb1075","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb1080","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1085","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1177\/09612033211028653","article-title":"10 years of belimumab experience: what have we learnt?","volume":"30","author":"Levy","year":"2021","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb1090","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb1095","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb1105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb1110","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two\u2013week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104079_bb1120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"issue":"9767","key":"10.1016\/j.autrev.2026.104079_bb1125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb1130","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb1135","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/ndt\/gfad167","article-title":"Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial","volume":"38","author":"Anders","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, randomized, fifty-two\u2013week study of the efficacy and safety of Belimumab in patients of black African ancestry with systemic lupus erythematosus","volume":"74","author":"Ginzler","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb1145","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"Brunner","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1150","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/ard-2024-225686","article-title":"Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study","volume":"83","author":"Aranow","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb1155","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb1160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1170","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104079_bb1175","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL - a proliferation inducing ligand - in autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J Autoimmun"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb1180","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2007-09-110858","article-title":"APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells","volume":"111","author":"Belnoue","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.autrev.2026.104079_bb1185","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.24628","article-title":"Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus","volume":"60","author":"Chu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"14","key":"10.1016\/j.autrev.2026.104079_bb1190","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1195","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of Atacicept in patients with systemic lupus erythematosus","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/art.39809","article-title":"Post hoc analysis of the phase II\/III APRIL-SLE study: association between response to Atacicept and serum biomarkers including BLyS and APRIL","volume":"69","author":"Gordon","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104079_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102976","article-title":"T follicular helper cells in autoimmune diseases","volume":"134","author":"Wei","year":"2023","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/cpt.2929","article-title":"Pharmacokinetics and pharmacokinetic\/Pharmacodynamic properties of Rozibafusp alfa, a bispecific inhibitor of BAFF and ICOSL: analyses of phase I clinical trials","volume":"114","author":"Abuqayyas","year":"2023","journal-title":"Clin Pharmacol Therap"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1220","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000890","article-title":"Improving resource utilisation in SLE drug development through innovative trial design","volume":"10","author":"Garces","year":"2023","journal-title":"Lupus Sci Med"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2026.104079_bb1225","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res"},{"issue":"6092","key":"10.1016\/j.autrev.2026.104079_bb1230","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.autrev.2026.104079_bb1235","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1177\/0961203309106183","article-title":"Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis","volume":"18","author":"Esposito","year":"2009","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1240","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb1245","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104079_bb1250","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb1255","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (\u03b1\/\u03b2) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history","volume":"19","author":"Fitzgeraldbocarsly","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.autrev.2026.104079_bb1270","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I interferons in autoimmunity","volume":"142","author":"Fernandez-Ruiz","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1275","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb1280","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti\u2013interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1285","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1290","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"McBride","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1295","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104079_bb1300","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104079_bb1305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1310","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1315","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1320","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104079_bb1325","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.autrev.2026.104079_bb1330","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1340","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.6004\/jnccn.2021.0054","article-title":"NCCN guidelines\u00ae insights: B-cell lymphomas, version 5.2021","volume":"19","author":"Zelenetz","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6382","key":"10.1016\/j.autrev.2026.104079_bb1345","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1350","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.autrev.2014.10.001","article-title":"Cell-based therapies for systemic lupus erythematosus","volume":"14","author":"Liao","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb1355","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2026.104079_bb1360","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb1365","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"482","key":"10.1016\/j.autrev.2026.104079_bb1370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104079_bb1375","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/art.42784","article-title":"CD19 chimeric antigen receptor T cell treatment: unraveling the role of B Cells in systemic lupus erythematosus","volume":"76","author":"Taubmann","year":"2024","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb1380","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.autrev.2026.104079_bb1385","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10437","key":"10.1016\/j.autrev.2026.104079_bb1390","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2026.104079_bb1395","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.autrev.2026.104079_bb1400","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1405","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.autrev.2026.104079_bb1410","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910845","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104079_bb1415","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8333","article-title":"\u0393-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.autrev.2026.104079_bb1420","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104079_bb1425","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell\u2013mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"issue":"10522","key":"10.1016\/j.autrev.2026.104079_bb1430","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2026.104079_bb1435","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.ard.2025.07.028","article-title":"Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus","volume":"84","author":"Fu","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:22:39Z","timestamp":1783120959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":287,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1568997226000935"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104079","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cells in systemic lupus erythematosus: from pathogenic mechanisms to targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104079"}}